FR17C1058I2 - Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids - Google Patents

Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids

Info

Publication number
FR17C1058I2
FR17C1058I2 FR17C1058C FR17C1058C FR17C1058I2 FR 17C1058 I2 FR17C1058 I2 FR 17C1058I2 FR 17C1058 C FR17C1058 C FR 17C1058C FR 17C1058 C FR17C1058 C FR 17C1058C FR 17C1058 I2 FR17C1058 I2 FR 17C1058I2
Authority
FR
France
Prior art keywords
bupropion
compositions
weight loss
opioid antagonist
influence weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1058C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexigen Therapeutics Inc
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04760321A external-priority patent/EP1617832B1/en
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of FR17C1058I1 publication Critical patent/FR17C1058I1/fr
Application granted granted Critical
Publication of FR17C1058I2 publication Critical patent/FR17C1058I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR17C1058C 2003-04-29 2017-12-08 Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids Active FR17C1058I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46683803P 2003-04-29 2003-04-29
EP07116330A EP1870096A3 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss
EP04760321A EP1617832B1 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss

Publications (2)

Publication Number Publication Date
FR17C1058I1 FR17C1058I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-01-12
FR17C1058I2 true FR17C1058I2 (fr) 2019-01-11

Family

ID=38719840

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1058C Active FR17C1058I2 (fr) 2003-04-29 2017-12-08 Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids

Country Status (6)

Country Link
EP (1) EP1870096A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2017C064I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1119418T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR17C1058I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00054I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300918I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012111011A2 (en) 2011-02-16 2012-08-23 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
EP2950799B1 (en) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
AU3419995A (en) * 1994-09-19 1996-04-09 Du Pont Merck Pharmaceutical Company, The Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
ES2393303T3 (es) * 1996-05-07 2012-12-20 Veroscience Llc Uso médico y composición para el tratamiento de trastornos del metabolismo de lípidos y de glucosa
WO1999038504A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
US6770620B2 (en) * 2000-09-18 2004-08-03 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
JP2005531557A (ja) * 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 選択的オピエート受容体モジュレーターとして効果的な化合物の使用
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake

Also Published As

Publication number Publication date
NL300918I1 (nl) 2017-12-14
CY2017041I2 (el) 2018-09-05
EP1870096A2 (en) 2007-12-26
CY2017041I1 (el) 2018-09-05
LUC00054I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-12-13
BE2017C064I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-08-09
NL300918I2 (nl) 2018-01-09
CY1119418T1 (el) 2018-03-07
FR17C1058I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-01-12
LUC00054I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-02-21
EP1870096A3 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
GB0318733D0 (en) Improvements in or relating to milking machines
GB0616752D0 (en) Formulation evaluation system and method
EP1755591A4 (en) OPHTHALMIC FORMULATIONS COMPRISING SELECTIVE ANTAGONISTS OF ALPHA RECEPTORS 1
SG111264A1 (en) Lubricant compositions
TWI345985B (en) Mild, moisturizing cleansing compositions
ZA200702131B (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof l
SG111310A1 (en) Lubricant compositions
FR2836389B3 (fr) Poids pour appareil de musculation
DE602004004278D1 (de) 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
EP1806982A4 (en) COMPOSITIONS AND METHODS FOR PROMOTING IMPROVEMENT OF WEIGHT AND FEED AID
PL1648882T3 (pl) 3-Fluoro-piperydyny jako antagoniści NMDA/NR2B
FR17C1058I2 (fr) Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids
GB0303678D0 (en) Improvements in or relating to flavour compositions
GB2419373B (en) Improvements in or relating to an access platform
ITMI20031166A1 (it) Sedile per apparati di divertimento.
GB0412204D0 (en) Horse food composition
GB0303675D0 (en) Improvements in or relating to flavour compositions
PT1684715E (pt) Composi??es compreendendo ciclo-hexilaminas e aminoadamantanos
IL157398A0 (en) Pharmaceutical compositions comprising ccr5 antagonists
GB0317398D0 (en) Improvements in or relating to an access platform
GB0303676D0 (en) Improvements in or relating to flavour compositions
GB0313682D0 (en) Cup trophy structure
GB0312345D0 (en) Improvements in compositions
GB0321410D0 (en) Improvements in or relating to compositions
FR2870738B1 (fr) Composition cosmetique comprenant des microspheres